List of Excipients in Branded Drug CARBIDOPA AND LEVODOPA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	ALCOHOL
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	AMMONIA
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	BUTYL ALCOHOL
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing CARBIDOPA AND LEVODOPA

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	carbidopa and levodopa	0093-9701	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	carbidopa and levodopa	0093-9701	FD&C BLUE NO. 2--ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	carbidopa and levodopa	0093-9701	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	carbidopa and levodopa	0093-9701	STARCH, CORN

What are the Most Frequently-Used Excipients in CARBIDOPA AND LEVODOPA?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
3	ASPARTAME
1	CALCIUM SILICATE
79	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Carbidopa and Levodopa

Last updated: February 27, 2026

What are the key excipient considerations for Carbidopa and Levodopa formulations?

Carbidopa and Levodopa (brand names such as Sinemet) require excipients that enhance stability, bioavailability, and patient tolerability. Typical excipients include stabilizers, fillers, disintegrants, and buffers. Their selection directly impacts drug shelf life, manufacturing process, and therapeutic efficacy.

Common excipient roles for these drugs:

• Disintegrants: Facilitate tablet breakup for optimal absorption.
• Binders: Ensure tablet cohesion during compression.
• Fillers/diluents: Adjust tablet size; common options include lactose, cellulose.
• Coatings and protective agents: Reduce gastric irritation, control release.
• Buffers: Maintain pH stability, essential for drug stability.

Challenges:

• Moisture sensitivity: Levodopa degrades rapidly in high humidity, requiring desiccants or moisture barriers.
• pH stability: Co-formulations often involve buffers to prevent degradation.
• Taste masking: For orally disintegrating formulations, excipients mask unpalatable taste.

How does excipient strategy influence formulation innovation?

Enhanced formulations incorporate novel excipients or delivery systems to improve bioavailability or reduce side effects. Examples include:

• Controlled release matrices: Use of hydroxypropyl methylcellulose (HPMC) to extend release.
• Physiologically targeted excipients: Lipid-based carriers deliver drugs directly to specific GI regions.
• Polymer matrices: For combination with microencapsulation, improving stability and patient compliance.

Formulators are increasingly exploring excipients that enable flexible dosing, rapid onset, or reduced peripheral side effects.

What are the commercial opportunities linked to excipient developments?

Market trends:

• Growing Parkinson’s disease prevalence: The global Parkinson's market is expected to reach USD 7.4 billion by 2028, with a CAGR of 4.4% (Research and Markets, 2021).
• Extended-release formulations: Capture premium pricing through improved patient compliance.
• Fixed-dose combinations: Simplify regimens; use excipients that permit stable multi-drug products.

Innovation avenues:

• Novel excipients: Gellan gum, sodium alginate, or modified starches that enhance stability.
• Advanced delivery systems: Liposomes, nanoparticles, or emulsions with excipients that target brain delivery.
• Taste-masking excipients: Improve patient adherence, especially in elderly populations.

Regulatory and supply chain considerations:

• Excipient sourcing must ensure batch-to-batch consistency and compliance with regulatory standards, such as USP, EP, or JP monographs.
• Patent landscapes for excipient innovations may provide exclusivity advantages.

How can companies leverage excipient strategies to gain competitive advantage?

• Formulation differentiation: Developing proprietary excipients or delivery systems that enhance efficacy or tolerability.
• Cost optimization: Selecting excipients that reduce manufacturing costs without compromising quality.
• Regulatory pathway acceleration: Using excipients with well-established safety profiles to expedite approvals.

Manufacturers investing in excipient research can produce differentiated products that command higher market share and address unmet patient needs.

Summary table: Excipient options and their clinical/market implications

Excipients	Role	Impact	Market Opportunity
Hydroxypropyl methylcellulose (HPMC)	Controlled-release matrix	Extended dosing intervals	Premium formulations
Gellan gum, sodium alginate	Mucoadhesive and targeted delivery	Potential for brain-targeted delivery	Niche, high-value therapies
Taste-masking agents	Palatability improvement	Better compliance in elderly patients	Over-the-counter or pediatric markets
Desiccants, moisture barriers	Stability during storage	Longer shelf life	Global markets with high humidity

Key Takeaways

• Excipients in Carbidopa and Levodopa formulations impact stability, bioavailability, and patient adherence.
• Innovations in excipient technology can facilitate controlled release, targeted delivery, and improved tolerability.
• The growing Parkinson’s market presents opportunities for formulations with advanced excipient systems.
• Regulatory compliance and supply chain stability for excipients are critical for commercialization.
• Companies that develop proprietary excipient systems or delivery platforms can differentiate their products and command higher premiums.

FAQs

What excipients are most commonly used in Levodopa/carbidopa tablets?
Lactose as a filler, microcrystalline cellulose as a binder, sodium starch glycolate as a disintegrant, and magnesium stearate as a lubricant.

How do excipients affect Levodopa stability?
Excipient interactions, especially with moisture, influence Levodopa's degradation rate. Stabilizers and moisture barriers are used to improve shelf life.

Are novel excipients necessary for next-generation formulations?
They are not always necessary but can enable controlled-release systems, targeted delivery, or taste masking, providing competitive advantages.

What regulatory hurdles exist for excipient modifications?
New excipients require safety and compatibility data; changes to existing excipients may need supplemental filings or reformulations.

How does excipient choice influence manufacturing costs?
Excipients differ in cost and processing requirements; selecting cost-effective, approved excipients optimally balances quality and profitability.

---

References

[1] Research and Markets. (2021). Parkinson’s Disease Therapeutics Market — Global Outlook and Analysis 2021-2028.